Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 10, 2015, Pages 1529-1535

  Chan, Stephen L ^a   Mo, Frankie ^a   Johnson, Philip ^c   Li, Leung ^a   Tang, Nelson ^b   Loong, Herbert ^a   Chan, Anthony W H ^a   Koh, Jane ^a   Chan, Anthony T C ^a   Yeo, Winnie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Infection; Liver neoplasm; Staging

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; DECARBOXYPROTHROMBIN; AFP PROTEIN, HUMAN; ALBUMINOID; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; ASSESSMENT OF HUMANS; BALAD SCORE; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHINESE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTEMIC THERAPY; BLOOD; CARCINOMA, HEPATOCELLULAR; COHORT ANALYSIS; COMPLICATION; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL RATE; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ALPHA-FETOPROTEINS; BILIRUBIN; BIOMARKERS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PROTHROMBIN; SURVIVAL RATE; TIME;

EID: 84941198657     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13005     Document Type: Article

References (27)

1. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-755.
2. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19: 329-338.
3. Johnson PJ, Berhane S, Kagebayashi C etal. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol. 2015; 33: 550-558.
4. Toyoda H, Kumada T, Osaki Y etal. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin. Gastroenterol. Hepatol. 2006; 4: 1528-1536.
5. Kudo M, Chung H, Haji S etal. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-1405.
6. Fox R, Berhane S, Teng M etal. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. Br. J. Cancer 2014; 110: 2090-2098.
7. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-1133.
8. Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol. 1994; 17: 71-91.
9. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
10. Kagebayashi C, Yamaguchi I, Akinaga A etal. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal. Biochem. 2009; 388: 306-311.
11. Harrell FE, Lee KL, Mark DB. Tutorial in biostatistics. Multivariable prognostic models issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
12. Kremers WK. Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. 2007. Available from URL: http://www.mayo.edu/research/documents/biostat-80pdf/doc-10027891 Assessed 6 June 2015.
13. Kudo M. Japan's successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance. Liver cancer. 2012; 1: 141-143.
14. Chan SL, Yeo W. Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how? Asia Pac J Clin Oncol. 2013; 9: 2-5.
15. Chan SL, Mo FK, Johnson PJ etal. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J. Gastroenterol. Hepatol. 2011; 26: 340-347.
16. Tangkijvanich P, Anukulkarnkusol N, Suwangool P etal. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J. Clin. Gastroenterol. 2000; 31: 302-308.
17. Chan SL, Chan AT, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both? Future Oncol. 2009; 5: 889-899.
18. Fujioka M, Nakashima Y, Nakashima O, Kojiro M. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology 2001; 34: 1128-1134.
19. Oka H, Saito A, Ito K etal. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J. Gastroenterol. Hepatol. 2001; 16: 1378-1383.
20. Hayashi K, Kumada T, Nakano S etal. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am. J. Gastroenterol. 1999; 94: 3028-3033.
21. Hoshida Y, Nijman SM, Kobayashi M etal. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009; 69: 7385-7392.
22. Motomura T, Shirabe K, Mano Y etal. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J. Hepatol. 2013; 58: 58-64.
23. Jang JW, Oh BS, Kwon JH etal. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine 2012; 60: 686-693.
24. Chan SL, Mo FK, Wong CS etal. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer 2012; 118: 3984-3992.
25. Pinato DJ, Stebbing J, Ishizuka M etal. A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI). J. Hepatol. 2012; 57: 1013-1020.
26. Hashimoto K, Ikeda Y, Korenaga D etal. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005; 103: 1856-1864.
27. Johnson PJ, Berhane S, Kagebayashi C etal. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncology. 2015; 33: 550-558.